← Back to Search

Insulin

Insulin Infusion versus Rotating Fluids for Diabetes

N/A
Waitlist Available
Led By Michael J Paglia, MD, PhD
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pregnant women with Type II diabetes mellitus or GDM controlled with insulin and/or hypoglycemic medication (GDMA2)
Be younger than 65 years old
Must not have
Active infection or immunocompromised state (e.g., HIV/AIDS, active malignancy, use of immunosuppressant medication) at time of admission for delivery
Women with Type 1 diabetes mellitus or use of insulin pump
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within one hour of delivery
Awards & highlights
No Placebo-Only Group

Summary

This trialwill compare IV fluid vs. insulin to control baby's blood sugar in laboring women with diabetes. A computer chooses the method.

Who is the study for?
This trial is for pregnant women with Type II diabetes or gestational diabetes controlled with insulin/medication, expecting to deliver at a Geisinger Medical Center between 37 and 40 weeks of gestation. They should be able to communicate in English or Spanish and not expected to deliver within 4 hours of joining the study.
What is being tested?
The study is testing if rotating IV fluids can better manage a baby's blood sugar after birth compared to using insulin infusion during labor. Women will be randomly assigned one of these two methods when they go into labor.
What are the potential side effects?
Potential side effects may include variations in blood sugar levels which could affect both mother and baby. The specifics will depend on individual reactions to either the rotating fluids protocol or the insulin infusion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am pregnant with Type II diabetes or gestational diabetes managed with insulin or medication.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have an active infection or a condition that weakens my immune system.
Select...
I am a woman with Type 1 diabetes or I use an insulin pump.
Select...
I am expected to give birth within 4 hours of joining the study.
Select...
My unborn baby has been diagnosed with a life-threatening condition.
Select...
I have taken oral corticosteroids within 48 hours before delivery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 24 hours of life until discharge (average time 21 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and first 24 hours of life until discharge (average time 21 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Neonatal blood glucose value
Secondary study objectives
Incidence of composite neonatal outcome
Hypoglycemia
Maternal blood glucose value before delivery
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Rotating fluidsActive Control1 Intervention
Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.
Group II: Insulin infusionActive Control1 Intervention
Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.

Find a Location

Who is running the clinical trial?

Geisinger ClinicLead Sponsor
155 Previous Clinical Trials
1,978,515 Total Patients Enrolled
Michael J Paglia, MD, PhDPrincipal InvestigatorGeisinger Clinic
1 Previous Clinical Trials
150 Total Patients Enrolled

Media Library

Insulin Infusion Protocol (Insulin) Clinical Trial Eligibility Overview. Trial Name: NCT03912363 — N/A
Gestational Diabetes Research Study Groups: Rotating fluids, Insulin infusion
Gestational Diabetes Clinical Trial 2023: Insulin Infusion Protocol Highlights & Side Effects. Trial Name: NCT03912363 — N/A
Insulin Infusion Protocol (Insulin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03912363 — N/A
~19 spots leftby Dec 2025